Navigation Links
Pulmo BioTech Announces an Increase in its Stake in PulmoScience
Date:5/9/2008

NEW YORK, May 9 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO) announced today that it has increased its stake in PulmoScience Inc. by 10%, taking its total holdings to 61% in this Company which owns a unique Molecular Imaging Diagnostic Technique for pulmonary related medical conditions.

Pulmo BioTech CEO Garry McCann said, "We are confident the Molecular Imaging technology, developed and owned by PulmoScience, will dominate the market for the diagnosis of Pulmonary Embolism and Pulmonary Hypertension, and as such, with the company moving towards Regulatory Approval for Phase I Human Trials, we felt that this was the right time to increase our stake in the company."

About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Pulmo BioTech's mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stock holders.

About PulmoScience Inc.

PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind.

The company was conceived within the Montreal Heart Institute "MHI" (a world renowned hospital and educational facility). Jointly owned by MHI subsidiary Innovacor as the technical and operational partner, Dr Jocelyn Dupuis (the scientific director and originator of the PulmoBind Molecular Imaging technology), and by Pulmo BioTech Inc as the funding partner, PulmoScience Inc aims to develop this unique and exciting technology, to fund necessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is worth in excess of $500 million per annum and that, provided Regulatory Approval is achieved, the safety and efficacy of its products could allow it to dominate that market.

About PulmoBind

PulmoBind uses an intravenously delivered radionuclide tagged molecule which specifically bonds to the inner walls of the circulatory system in the lungs, and by the use of an external Gamma Camera allows an image of the integrity of the blood vessels throughout the lungs to be seen by a diagnostic clinician. PulmoScience is currently undertaking Regulatory Approval for Phase I Human Trials, and while subsequent results from additional tests might not corroborate the current results, PulmoScience believes that PulmoBind has the potential to dominate the market for the diagnosis of Pulmonary Embolism. In particular, this belief is driven by PulmoScience's expectations of the improved safety and efficacy that PulmoBind will offer when compared to the current incumbent nuclear medicine based technology for the diagnosis of Pulmonary Embolism. In addition, early indications are that PulmoBind could be highly effective in the early stage diagnosis of Pulmonary Hypertension, a condition for which there is no current front line diagnostic test. The addressable market for the product candidates being developed by PulmoScience is believed by the company to be worth in excess of $500 million per annum.

Forward-Looking Statements

Forward-looking statements contained in this and other written and oral reports are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. All statements regarding future performance, earnings projections, regulatory approval, events or developments are forward-looking statements. It is possible that the future performance and of the company may differ materially from current expectations, depending on economic conditions and the uncertainty of regulatory approval. A change in economic conditions may have a particularly volatile effect on results. Among the other factors which may affect future performance are: competitive market conditions and resulting effects on sales and pricing; increases in raw-material costs that cannot be recovered in product pricing; and global economic factors, including difficulties entering new markets and general economic conditions such as inflation, interest rates and credit availability. The company makes these statements as of the date of this disclosure, and undertakes no obligation to update them.


'/>"/>
SOURCE Pulmo BioTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
2. Pulmo BioTech Announces Appointment of Chief Financial Officer
3. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
4. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
5. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
6. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
7. Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology
8. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
9. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
10. DuPont Strengthens Commitment to Responsible Science with New Biotech Advisory Panel Members
11. Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017   Enteris BioPharma, Inc. ... agreement with Sanofi to leverage Enteris, proprietary ... Peptelligence™, to develop an oral formulation of one of ... Tune , Chief Executive Officer and Executive Chairman of ... validation of the tremendous value our Peptelligence platform program ...
(Date:1/23/2017)... 2017 Atlas Genetics Ltd., the ultra-rapid ... Series D financing, raising $35 million from a syndicate including ... ... of the Atlas Genetics io® system has been completed with ... announced in February 2016.  This new Series D equity issue ...
(Date:1/23/2017)... , Jan. 23, 2017  Alkahest Inc. ... treatments for neurodegenerative diseases and other age-related conditions, ... the company as Chief Medical Officer. In this ... clinical development activities at Alkahest and serve on ... most recently served as Executive Director at Dynavax, ...
(Date:1/23/2017)... Utah (PRWEB) , ... January 23, 2017 , ... ... been named an INTERNET TELEPHONY Product of the Year Award winner for 2017. ... industry leader in unified communications solutions. In 2016, CallTower was awarded with the hosted ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in mobile ... market" The mobile biometrics market is expected to grow ... billion by 2022, at a CAGR of 29.3% between ... such as the growing demand for smart devices, government ... "Software component is expected to grow at ...
(Date:12/8/2016)... Dec. 8, 2016 Market Research Future published a half ... global Mobile Biometric Security and Service Market is expected to grow ... Market Highlights: ... , Mobile Biometric Security and ... the increasing need of authentication and security from unwanted cyber threats. ...
(Date:12/7/2016)... India , December 7, 2016 According to a ... Machine Learning), Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, ... is estimated to grow from USD 6.72 Billion in 2016 to USD 36.07 ... Continue Reading ... ...
Breaking Biology News(10 mins):